Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers
| Autor: | Li W, C H Weaver, WH West, FA Greco, J Hainsworth, Lee S. Schwartzberg, Buckner Cd |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment ThioTEPA Lower risk chemistry.chemical_compound Breast cancer Risk Factors Internal medicine Neoplasms Antineoplastic Combined Chemotherapy Protocols medicine Humans Multiple myeloma Transplantation Chemotherapy business.industry Age Factors Hematopoietic Stem Cell Transplantation Cancer Hematology medicine.disease Combined Modality Therapy Carboplatin Surgery Clinical trial Treatment Outcome chemistry business medicine.drug |
| Zdroj: | Bone marrow transplantation. 19(7) |
| ISSN: | 0268-3369 |
| Popis: | Summary: cancer centers. 10‐14 This report describes the 100-day treatment-related mortality (TRM) of the first 1000 consecutive patients receiving high-dose myeloablative chemotherapy High-dose chemotherapy (HDC) with autologous peripheral blood progenitor cell (PBPC) is being increas- within a multicentered community-based clinical trials program. ingly utilized as a therapeutic modality for patients with chemotherapy-sensitive disease. Several published HDC regimens have become relatively widely used. The purpose of this analysis was to determine treatment-related Materials and methods mortality (TRM) following administration of five different HDC regimens in community cancer centers. A Patient selection retrospective evaluation of 1000 consecutive patients Between February 1989 and 15 September 1994, 1000 conwith leukemia, non-Hodgkin’s lymphoma, Hodgkin’s secutive patients were enrolled on protocols administering disease, multiple myeloma, sarcoma, ovarian cancer, or HDC. 10‐13 Patients were eligible for study if they had a breast cancer who received one of five published HDC malignant disease that could potentially benefit from HDC, regimens followed by PBPC infusion over a 5-year per- were between age 18‐65 years, had ECOG performance iod in community cancer centers was performed to status of 0‐2 and evidence of adequate hepatic, renal and determine TRM. Fifty-nine patients (5.9%) died within cardiac function. Patients were treated on clinical protocols 100 days of PBPC infusion. Twenty-five patients (2.5%) designed by investigators of Response Oncology Inc (ROI) died predominantly of causes related to disease pro- and approved by the institutional review board of the hospigression. Thirty-four patients (3.4%) died of TRM, 15 tal where the therapy was administered and all patients patients (1.5%) died from infection and 19 (1.9%) died signed a protocol-specific informed consent. from regimen-related toxicities (RRT). In a logistic model, increasing age (P = 0.001) and lower numbers of CD34 + cells/kg (P = 0.003) were associated with an Treatment centers increased risk of 100-day TRM. High-dose cyclophosPatients analyzed for this report were treated in 28 medical phamide, thiotepa, and carboplatin was associated with centers in the US under the care of 159 community medical a lower risk of mortality than other regimens (P = |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|